Additionally, because the enzyme activities remain stable over several days, mailing to specialized centers is easier and less expensive. Furthermore, the assay requires only a few drops of blood in contrast to the 2-5 mL of EDTA blood needed for leukocyte assays. We consider the dried blood tests for PPT1 and TPP1 a very useful approach to the diagnosis of CLN1 and CLN2. However, the diagnosis should be confirmed by DNA tests, electron microscopy, and enzyme measurements in skin fibroblasts if only very low or no enzyme activities are detectable.
Measurement of C-reactive protein (CRP) is used for conventional inflammation diagnosis (1 ) and diagnosis of low-grade inflammation for risk estimation of cardiovascular events (2, 3 ) . Because diagnostic measurement ranges for those two indications differ by two orders of magnitude, different methods or different applications of one method must be used at present to cover both diagnostic measurement ranges (4, 5 ) . The aim of this study was to evaluate the analytical performance of the Denka Seiken turbidimetric CRP assay compared with the Dade Behring nephelometric assay across a concentration range of 0.2-300 mg/L. For this evaluation, leftover material was used, which is in concordance with the European Law for Medical and Diagnostic Products.
For precision and linearity studies, we prepared serum pools from blood samples with previously measured CRP (BN II nephelometer; Dade Behring). The low and high pools were prepared by combining samples with CRP Ͻ1 and 200 -300 mg/L, respectively. The high pool was diluted with the low pool to the following final percentages of high pool: 100%, 33%, 11%, 3.7%, 1.2%, 0.41%, 0.14%, and 0%. The dilutions were aliquoted and stored at Ϫ20°C for a maximum period of 4 weeks until use. Both CRP methods were used according the manufacturers' instructions. The turbidimetric wide-range CRP assay provided by Denka Seiken [CRP-latex (II)X2 assay, calibrated against reference preparation CRM 470] was performed on a Hitachi 911 (Roche), and the nephelometric assay provided by Dade Behring was performed on a BN II nephelometer (Dade Behring).
To examine the precision of the Denka Seiken method compared with the established method, aliquots of serum pool dilutions were measured in duplicate on 10 different days (Table 1) . CVs were Յ6.8% for the Denka Seiken method and Յ4.4% for the Dade Behring method. For all To study the linearity of each method, we calculated the target concentrations of pools 2-7 from the mean concentrations of pool 1 (100% high pool) and pool 8 (100% low pool) as measured by the respective methods. Table 1 shows the calculated target concentrations of the pool dilutions as well as the percentages of deviation of the measured concentrations from the respective targets To study the concordance of results obtained from plasma and serum samples, we analyzed 30 pairs of heparin and serum samples from the same blood donation with the Denka Seiken method. Deming regression analysis of these measurements revealed optimum correlation: y ϭ 1.00x Ϫ 0.006 mg/L [r ϭ 1.000; range, 0.3-83 mg/L; mean (SD) 24.9 Ϯ 26.6 mg/L in serum vs 24.8 Ϯ 26.5 mg/L in plasma].
To study the correlation of the Denka Seiken method with the comparison method, we collected 191 serum and 19 heparin-plasma samples from routine requests for traditional CRP analysis or high-sensitivity CRP. Of these, 108 samples had concentrations Ͻ5 mg/L and 102 had concentrations Ͼ5 mg/L. The samples were then analyzed with the Denka Seiken and the comparison method (Fig. 1) . Fig. 1 shows that at concentrations Ͻ5 mg/L, the slope was higher for the Denka Seiken method compared with the Dade Behring method (slope, 1.15; intercept, 0.09 mg/L; S y͉x ϭ 0.14 mg/L; r ϭ 0.986). At concentrations Ͼ5 mg/L, however, the slopes were close to the lines of unity for both methods (slope, 1.03; intercept, 0.11 mg/L; S y͉x ϭ 3.76 mg/L; r ϭ 0.998). This bend in the slopes might be attributed to the opposite nonlinearity between the Denka Seiken method and the Dade Behring method, as shown in Table 1 .
To evaluate the concordance of both method in cardiovascular risk assessment, the recently proposed cutoff values for the Dade Behring method (6 ) were adjusted for the Denka Seiken method by the regression equation calculated from patient samples Ͻ5 mg/L (Fig. 1B) . At these adjusted cutoff values, 96% of patients were allocated to identical risk groups. No patient was mismatched more than one adjacent risk group.
In conclusion, the linearity of the Denka Seiken CRP assay is slightly better than that of the comparison method. Because of the bend in the linearity curve for the Dade Behring method, correlation of patient values revealed different slopes at high and low CRP concentrations. Therefore, sufficient concordance between methods for cardiovascular risk estimation might be obtained only after adjustment of cutoff values by the regression equations. The Denka Seiken CRP assay covers in a single determination the ranges for diagnosis of both conventional and low-grade inflammation. This method therefore improves laboratory throughput by reducing the number of retests with different sample dilutions or a different method. 
